A quiet shift, yet a profound one. 🧠
The OCEANIC-STROKE trial introduces asundexian, a Factor XIa inhibitor that lowers recurrent ischemic stroke risk (HR 0.74) without increasing major bleeding—a long-sought balance in antithrombotic therapy.
For decades, we traded efficacy for safety. Now, we may finally have both. ⚖️
The implications extend beyond stroke—to a broader rethinking of thrombosis itself: can we uncouple clot from bleed?
This study suggests we can.
#StrokePrevention #Cardiology #Neurology #ClinicalTrials #Anticoagulation #PrecisionMedicine
